{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:43:50Z","timestamp":1790826230635,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ymgme.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:07:21Z","timestamp":1649678841000},"page":"152-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program"],"prefix":"10.1016","volume":"136","author":[{"given":"Jerry","family":"Vockley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Enns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Nino","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Reineking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.04.001_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2016.08.008","article-title":"Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders","volume":"119","author":"Vockley","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0010","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.37765\/ajmc.2020.88480","article-title":"Long-chain fatty acid oxidation disorders and current management strategies","volume":"26","author":"Vockley","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10545-009-9001-1","article-title":"Fatty acid oxidation disorders: outcome and long-term prognosis","volume":"33","author":"Wilcken","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11154-020-09568-3","article-title":"Clinical manifestations and management of fatty acid oxidation disorders","volume":"21","author":"Merritt","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/cvr\/cvt212","article-title":"Myocardial energy shortage and unmet anaplerotic needs in the fasted long-chain acyl-CoA dehydrogenase knockout mouse","volume":"100","author":"Bakermans","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10545-006-0320-1","article-title":"Anaplerotic molecules: current and future","volume":"29","author":"Brunengraber","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bbadis.2014.02.001","article-title":"Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(\u2212\/\u2212)) mice","volume":"1842","author":"Tucci","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cvr\/cvr038","article-title":"Modulating fatty acid oxidation in heart failure","volume":"90","author":"Lionetti","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2015.06.006","article-title":"Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment \u2013 a retrospective chart review","volume":"116","author":"Vockley","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3476(98)70385-3","article-title":"Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life","volume":"132","author":"Boles","year":"1998","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10545-012-9542-6","article-title":"Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients","volume":"36","author":"Baruteau","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/adc.84.1.58","article-title":"A severe genotype with favourable outcome in very long chain acyl-CoA dehydrogenase deficiency","volume":"84","author":"Touma","year":"2001","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ymgme.2020.10.001","article-title":"Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach","volume":"131","author":"Van Calcar","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0070","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0022-3476(81)80834-7","article-title":"Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency","volume":"98","author":"Bougn\u00e8res","year":"1987","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0075","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1023\/A:1005556207210","article-title":"Recognition and management of fatty acid oxidation defects: a series of 107 patients","volume":"22","author":"Saudubray","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0080","article-title":"Physiological perspectives on the use of triheptanoin as anaplerotic therapy for long chain fatty acid oxidation disorders","volume":"11","author":"Sklirou","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0085","series-title":"Dojolvi PI","year":"2020"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0090","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s40265-020-01399-5","article-title":"Triheptanoin: First Approval","volume":"80","author":"Shirley","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2021.02.003","article-title":"Clinical outcomes in a series of 18 patients with long chain fatty acids oxidation disorders treated with triheptanoin for a median duration of 22 months","volume":"132","author":"Guffon","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1172\/JCI0215311","article-title":"Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride","volume":"110","author":"Roe","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jimd.12313","article-title":"Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: results from an open-label, long-term extension study","volume":"44","author":"Vockley","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jimd.12038","article-title":"Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD)","volume":"42","author":"Vockley","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-020-01635-x","article-title":"Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders","volume":"16","author":"Zoggeler","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ymgme.2015.10.005","article-title":"Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: review of 15 years experience","volume":"116","author":"Roe","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100069","article-title":"Octanoate is differentially metabolized in liver and muscle and fails to rescue cardiomyopathy in CPT2 deficiency","volume":"62","author":"Pereyra","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2022.04.001_bb0130","series-title":"Left Ventricular Ejection Fraction, StatPearls","author":"Kosaraju","year":"2021"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/01.CIR.99.10.1337","article-title":"Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death","volume":"99","author":"Mathur","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2022.04.001_bb0140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-6-44","article-title":"Efficacy and outcome of expanded newborn screening for metabolic diseases \u2013 report of 10 years from South-West Germany","volume":"6","author":"Lindner","year":"2011","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222002979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222002979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:52:54Z","timestamp":1761090774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222002979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1096719222002979"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.04.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}